All In Biotech

Drug Trial Radar · NCT01524198

The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room

Last checked: Nov 20, 2026Latest source record: Mar 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 945 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

945

Actual

Start

Nov 2010

Primary completion

Apr 2012

Study completion Apr 2012

Sponsor

Lead sponsor
King Saud UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
King Fahad Medical City
First posted
Feb 1, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Asthma is the most common chronic illness of childhood. About 10% of children are affected. Not surprisingly, acute asthma exacerbations are one of the common reasons to visit pediatric emergency rooms (ER). About 5.7% of all pediatric emergency room visits are due to acute asthma exacerbation. Around 8% of those get admitted to the hospital. This constitutes huge financial and administrative burden on the health care system. Inhaled corticosteroids (ICS) is the gold standard prophylactic therapy for patients with persistent asthma. In the setting of acute asthma exacerbation systemic steroids given early in the course of treatment help decrease the rate of admission and return to the ER. However, the anti-inflammatory action of corticosteroids, through which this effect is caused, takes 4 hours to start working. This is because it is mediated through genomic pathways where the transcription of several inflammatory cytokines is suppressed. It was also shown that corticosteroids can cause vasoconstriction through non-genomic pathways. The onset of this action is as quick as 30-60 minutes. It is proposed that this action is mediated by blocking the extraneuronal uptake (metabolism) of norepinephrine in vascular smooth muscle cells, hence, making it available for re-use by the sympathetic neuronal cells. Our objective is to compare the efficacy of adding repetitive sequential doses of budesonide versus placebo (normal saline (NS)) to β2-agonist and ipratropium bromide (IB) combination (standard treatment) in the management of acute asthma in children in the ER. We hypothesize that the addition of budesonide to β2-agonist and IB in the management of moderate to severe acute asthma in the ER is superior to the addition of placebo.

Conditions

  • Status Asthmaticus

Interventions

  • BudesonideDrug

    500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back

  • Normal salineDrug

    0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients Hospitalization RateTime frame: 17 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • King Fahad Medical City

    Riyadh, Riyadh Region, Saudi Arabia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.